AbbVie (ABBV) EPS (Basic) Growth (1y) (2013 - 2026)
Powered by 
Analysis
AbbVie (ABBV) EPS (Basic) Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -15.94% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 39.99% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 13.91% |
| 10 | Jazz Pharmaceuticals | 16.02 Bn | 14.40 Bn | 1.09 Bn | 126.00% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 284.05% |
| Mar 31, 2026 | -45.99% |
| Dec 31, 2025 | 7,991.30% |
| Sep 30, 2025 | -87.98% |
| Jun 30, 2025 | -31.46% |
| Mar 31, 2025 | -6.00% |
| Dec 31, 2024 | -102.79% |
| Sep 30, 2024 | -12.28% |
| Jun 30, 2024 | -32.30% |
| Mar 31, 2024 | 1,515.23% |
| Dec 31, 2023 | -66.61% |
| Sep 30, 2023 | -54.83% |
| Jun 30, 2023 | 118.80% |
| Mar 31, 2023 | -102.16% |
| Dec 31, 2022 | -38.92% |
| Sep 30, 2022 | 24.21% |
| Jun 30, 2022 | 20.61% |
| Mar 31, 2022 | 26.24% |
| Dec 31, 2021 | 9,925.30% |
| Sep 30, 2021 | 37.41% |